Affiris, European Patent for Alzheimer’s Vaccine

November 2007. Affiris GmbH has been granted a Europe-wide patent for key elements of its Alzheimer’s vaccine. As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial... [PDF] Affiris' Press Release -

Biogen Idec and Neurimmune Therapeutics, ALLIANCE TO DEVELOP TREATMENTS FOR ALZHEIMER’S DISEASE

November 20, 2007 - Biogen Idec (NASDAQ: BIIB) and Neurimmune Therapeutics AG today announced they have entered into an agreement for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer's disease (AD)...Neurimmune will conduct research to identify potential therapeutic antibodies using the company's Reverse Translational Medicine (RTM) platform. Biogen Idec will be responsible for the development and commercialization of all products... Biogen's Press Release - Neurimmune's Press Release -

EPIX Pharmaceuticals , Second Discovery Program in Collaboration with GlaxoSmithKline

Nov. 5, 2007-... In December 2006, EPIX and GSK announced a worldwide multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX's novel 5-HT4 partial agonist program, PRX-03140, which is in early-stage clinical development for the treatment of Alzheimer's disease... EPIX 's Press Release -

Pipex Pharmaceuticals, Anti-Copper COPREXA Demonstrates 40% Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer’s Disease

November 5, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX: PP) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced the presentation of preliminary results using its lead anti-copper drug candidate, COPREXA (oral tetrathiomolybdate), in the most commonly utilized transgenic pre-clinical murine model of Alzheimer’s Disease (AD) at the 2007 Society for Neuroscience annual meeting on November 4th in San Diego, CA... Pipex Pharmaceuticals' Press Release -